The mechanism of severe hyperlipidemia in a 54-year-old womanwith multiple myeloma and monoclonal immunoglobulin A (IgA) gammopathywas investigated. Her plasma total cholesterol and triglyceride concentrations were 29.7 mmol// (1,150 mg/dl) and ll.9 mmol// (1,060 mg/dl),
Introduction
Severe hyperlipoproteinemia with increased plasma concentrations of cholesterol and triglyceride is caused by various kinds of primary and secondary etiologies such as apo E2/E2 homozygotes (1, 2) or apoE deficiency (3, 4) as the primary cause or hypothyroidism or diabetic hyperlipidemia as the secondary cause. Amongthese, the presence of autoimmunity has been noted as a rare cause of severe hyperlipidemia. The concept of autoimmune hyperlipidemia was proposed originally by Beaumont et al (5) . Since then, hyperlipidemic patients with autoantibodies to circulating lipoproteins as well as enzymes related to lipoprotein metabolism have been documented. However,the mechanismremains speculative except in a few cases. Corsini et al have reported one patient with autoantibodies to the low density lipoproteins (LDL) receptor (6) and, wehave previously described a patient with autoimmune hyperchylomicronemiadue to autoantibodies against lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) (7). The current report presents a patient with multiple myeloma associated with severe hyperlipoproteinemia, xanthomatosis, and monoclonal immunoglobulin A (IgA) gammopathy, whose clinical findings have been previously described (8). Although the mechanism in which antibody inhibits the LDLbinding to the LDL receptor in cells is suspected as a cause of hyperlipidemia, the presence of such antibodies has not been clarified in similar cases previously reported (9-1 1). Here, for the first time, we have identified an inhibitory antibody against LDLbinding to fibroblasts in the present case.
Case Report
The proband was a 54-year-old Japanese woman,who was initially admitted to the National Fukuoka Central Hospital in 1987 at the age of48 years with a pathologic fracture of the neck of the left femur due to an osseous xanthoma (8). Physical examination on the first admission revealed widespread xanthomatosis involving the elbows, knees, palms, interdigital regions, inguinal region, chest, and hips. In addition, the ocular fundi were filled with xanthomas. Examination of a bone marrowspecimen demonstrated that foam cells accounted for 8%of the cell population and plasma cells for 6%. No hepatomegaly or splenomegaly was observed. Laboratory tests revealed a normocytic anemia (hemoglobin: 92 g//) and severe hyperlipidemia (total cholesterol: 29.7 mmol// ( 1 , 150 mg/dl), triglyceride 1 1.9 mmol// (1,060 mg/dl), high-density lipoprotein (HDL) cholesterol: 1.24 mmol// (48 mg/dl)). The electrophoretic separation of serum lipoproteins on agarose gel on admission had revealed no definite broad beta band. Analysis of the apo E phenotype showed E3/E2. LPL and HTGLactivities were both normal. There were no signs of atherosclerotic cardiovascular diseases, diabetes mellitus , thyroid dysfunction, or renal disease.
Since her first admission, the patient stopped drinking alcohol and she has been treated with a low calorie, low cholesterol diet (1 ,600 kcal/day, fat 20 g/day, cholesterol 250 mg/day) and lipid-lowering agents including probucol, cholestyramine, clofibrate, niceritrol and pravastatin. These treatments reduced the patient's serum total cholesterol concentrations to 6.5-7.7 mmol// and her triglyceride concentrations to 1.5-3.4 cholesterol and triglyceride also decreased in spite of stopping the hyperlipidemic treatment. The serum levels of IgA, total cholesterol, triglyceride were followed in the period from 1983-1997 (Fig. 1 ). As shown in Fig. 1 Figure 1 . Serum levels of IgA, total cholesterol, and triglyceride in the period from 1983-1997. The levels of serum cholesterol and triglyceride were parallel with the levels of IgA. The dosage per day of medications is indicated in each box. MPTx: melphalan 6 mg and prednisolone 30 mg per day for 5 consecutive days, T-CHOL: total cholesterol, TG: triglyceride, HDL-C: HDLcholesterol, BW:body weight.
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To study the binding of IgA to LDL, lipoprotein-deficient serum (LPDS) from the patient or a control subject was incubated with 5 |ig of control LDLfor 2 hours at room temperature, then subjected to non-denaturing polyaerylamide gradient gel electrophoresis (PAA4/30). Next, the gels were transferred to a nitrocellulose membraneand incubated with anti-human IgA as described above.
IgA purification
IgA was partially purified from serum using Jacalin ( 15 (16, 17). Briefly, the cultured normal skin fibroblasts were washed twice with MEMand preincubated for 48 hours with MEMcontaining 10% (v/v) LPDS. On the day of the experiment, the binding of 125I-LDL was measured by incubating cells at 4°C for 1 hour. Cell association and degradation of 125I-LDL in fibroblasts were determined after 4 hours of incubation at 37°C with 125I-LDL. After washing the cells with washing buffer (0. 15 mol// NaCl, 50 mmol// Tris-HCl, pH 7.4) three times, the cells were dissolved in 1.0 ml of0.1 N NaOH and the radioactivity was measuredas cell association or binding of lipoproteins.
The degradation of 125I-LDL was quantitated by the measurement of trichloroacetic acid-soluble noniodide radioactivity in the media after incubation. Specific values were determined by subtracting the values in the presence of 40-fold excess amounts of unlabeled LDL.
Results

Lipoprotein profiles
The administration of serum lipid-lowering agents could not be discontinued in this patient because of the severe hyperlipoproteinemia and xanthomatosis. Accordingly, the lipoprotein profile of this patient was obtained during the administration of a combination of multiple hypolipidemic agents (clofibrate, 600 mg/day; cholestyramine, 1 2 g/day; niceritrol, 1 g/day; probucol, 750 mg/day; and pravastatin, 10 mg/day). Serumcholesterol and triglyceride concentrations were 9.0 mmol// (348 mg/dl) and 1.6 mmol// (141 mg/dl), respectively. VLDL,LDL, HDL2, and HDL3cholesterol levels were 0.23, 6.9, 0.74, and 1.1 1 mmol//, respectively. Apolipoprotein A-I, A-II, B, C-II, C-III and E levels were 0.88, 0.41, 1.53, 0.061, 0. 108, and 0. 105 g//, respectively. The serum concentrations of LDLcholesterol, apo B, and apo E were resistant to such intensive treatment and remained elevated, while the level of apo A-I was below the level observed in 14 normal controls (mean ± SD control ranges for apoA-I, A-II, B, C-II, C-III, and E were 1.49 ± 0.22, 0.38 ± 0.06, 0.91 ± 0.25, 0.037 ± 0.012, 0.083 ± 0.027 and 0.041 ± 0.01 1 g//, respectively).
Detection of IgA in the LDLfraction of the patient The LDLfraction of the patient was shown by western blot analysis to contain IgA, while the LDLfraction from control subjects contained little IgA (Fig. 2) . The VLDLfraction from the patient also contained IgA. However, the HDLfraction from both the patient and control did not contain IgA (data not shown).
IgA binding to LDL LPDSfrom the patient or a control subject was incubated with control LDLfor 2 hours at room temperature. The mixture was applied to a polyacrylamide gradient gel and transferred to a nitrocellulose membraneas described in the Methods. The membranewas analyzed using anti-human IgA, revealing that patient IgA bound to LDLafter preincubation with patient LPDS and control LDL, whereas LDL preincubated with control LPDSwas not associated with IgA. These data suggest that the patient's IgA bound to LDL (Fig. 3) . from the patient was added to media containing 5 jag of 125I-LDL. Both the binding and degradation of 125I-LDL in fibroblasts were markedly reduced compared with those obtained by the addition of control LPDS. Partially purified IgA from the patient also inhibited the binding and degradation of 125I-LDL in fibroblasts (Fig. 4) . In order to study whether or not the patient's IgA bound to LDLreceptors on fibroblasts, LPDSfrom a control and the patient was preincubated with fibroblasts for 1 hour at 37°C; next, the mediumwas removed. 125I-LDLwas then added and fibroblasts were incubated at 37°C for 4 hours. There was no significant difference in the cell association of 125I-LDL in the fibroblasts preincubated with LPDSfrom a control subject versus that from the patient (1,100± 85 vs 1,065 ±76 ng LDL/ mg of cell proteins, respectively). These findings suggest IgA does not act as an autoantibody to the LDLreceptor as reported by Corsini et al (6). Next, the binding site of IgA to LDLwas investigated. Control VLDLwas delipidated with ethanol/ether (v/v:3/l ) and subjected to SDS-PAGelectrophoresis. The gel was then transferred to a nitrocellulose membrane.Themembranewas incubated with 10%LPDSfrom the subject and a control for 24 hours. Proteins were subsequently detected with peroxidaseconjugated anti-human IgA. No bands were detected in membranes incubated with LPDSfrom the patient and a control, suggesting that the IgA did not bind apoVLDL(data not shown).
Discussion
The current study has clarified the mechanismof severe hyperlipidemia in a patient whopresented with monoclonal IgA gammopathy. Analysis of the patient' s IgA revealed that it I 1'000! l 1'500^ĝ IgA concentration (jug/ml) IgA concentration (jug/ml) Figure 4 . Effects of control and patient IgA on binding and degradation of 125I-LDL in fibroblasts. Fibroblasts were preincubated with normal human LPDSfor 48 hours. On the day of the experiment, the mediumwas changed. Next, 5 Jig/m of125I-LDLwas added to the fibroblasts with or without the amounts of control or patient IgA as indicated in the figure and incubated for 1 hour for binding and 4 hours for degradation. Binding and degradation were determined as described in the Methods.
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Before the administration of lipid-lowering agents, this patient exhibited markedly elevated serum total cholesterol and triglyceride concentrations with systemic xanthomatosis. Even when we analyzed the lipoprotein levels during the administration ofhypolipidemic medications, the plasma LDLcholesterol concentrations were still high.
Furthermore, we investigated the role of monoclonal IgA in the hyperlipidemia of this patient. The presence of immunoglobulin and lipoprotein (Ig-Lp) complex in multiple myeloma or paraglobulinemia has been reported in several studies (1, 9-1 1, 18, 19) . Autoantibodies to LP-receptors, theirligands, or lipolytic enzymes in plasma have been suggested as basic components of the mechanismof autoimmunehyperlipidemia. However, in most of these reports, it still is unclear why Ig-Lp complexes cause hyperlipidemia, and there have been very few reports addressing the role of the Ig-Lp complex in the pathophysiology of hyperlipidemia (2, 3) . In some cases the Ig-Lp complex does not interfere with the metabolism of LDL(20 
